Ultrasensitive ctDNA Shows Promise in Immunotherapy Monitoring
FREMONT, Calif., Feb. 2, 2026 — Personalis announced the publication of new peer-reviewed clinical evidence demonstrating the value of...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
FREMONT, Calif., Feb. 2, 2026 — Personalis announced the publication of new peer-reviewed clinical evidence demonstrating the value of...
Boston, MA – December 2025 – The global Clinical Oncology Next-Generation Sequencing (NGS) market is expanding rapidly as cancer...
MANHASSET, N.Y. — November 27, 2025: Feinstein Institutes for Medical Research, in collaboration with Stony Brook University and Texas...
YONGIN, South Korea — November 27, 2025: GC Genome has announced the publication of its landmark study on a...
